GREY:ATBPF - Post by User
Comment by
MrMugsyon Aug 27, 2023 11:50am
240 Views
Post# 35607229
RE:RE:RE:RE:Concentration
RE:RE:RE:RE:ConcentrationThere are a few other opportunities that will play a roll if/when acute has success and they are as follows:
1. an additional group of buyers who try to stay away from NA medicines because of the dangers associated with NSAIDs and opioids.
2. Doctors/patients who limit consumption for fear of NSAIDs and opioids.
3. a move to chronic for OTENA ... be it for full chronic use or for flare-ups only.
----------
I am of the belief that OTENA has a place in chronic regardless of the formulation (old or new). It now likely has a bigger place with the new formulation and the extened IP.
For example, there are an infinite number of ways to administer OTENA for flare-ups and that will quickly become evident.
Also - the P3 trial for chronic will be long - true - but that doesn't mean we can't see value for chronic sooner than later.
----------
I know - this all seems very distant in the future ... but ... not necessarily.
There are interesting scenarios that can develop .. IF ... OTENA acute can get through P2 with huge success. IMO
Nothing is simple though, takes a team that sees far enough into the future to make the tough decisions and to pivot to create the value. Not aways obvious from a shareholder's perspective.
Good Luck Team.